Primer Capital
Primer Capital is a venture capital firm based in Moscow, Russia, that specializes in early-stage investments in the healthcare, pharmaceutical, and biotechnology sectors. Established in 2015, the firm primarily focuses on projects related to oncology, cardiology, rheumatology, surgery, medical devices, and drugs, including generic and biosimilar products. Primer Capital typically invests between $0.2 million and $0.5 million and is open to co-investments alongside other venture capital funds and investors. The firm benefits from a team of qualified consultants and a Scientific Advisory Board composed of experts in various medical and biopharmaceutical fields, which enhances its project selection process. Primer Capital collaborates with venture capital partners, business angels, and governmental agencies to promote the development of the biopharmaceutical industry and support its portfolio companies in establishing effective partnerships and securing additional funding throughout their growth trajectory.
Botkin.AI is a software platform specializing in medical image processing and analysis through artificial intelligence. Founded in 2015 and based in Moscow, the company focuses on enhancing the capabilities of radiologists by providing advanced tools for analyzing radiograms and assessing the risk of tumors. Utilizing deep machine learning, Botkin.AI's technology enables healthcare providers to diagnose oncological diseases, such as lung cancer, with high accuracy and at early stages. By streamlining the processing of clinical data, the platform improves diagnostic efficiency while maintaining the quality of medical conclusions, ultimately supporting better patient outcomes.
GemoPharm is a biotechnology company focused on developing innovative therapies for cancer treatment, particularly targeting relapsed or refractory primary and secondary central nervous system lymphomas and intraocular lymphomas. Its lead asset is a monoclonal antibody derived from a proprietary therapeutic platform that selectively targets CD71 in the tumor microenvironment. This targeted approach aims to reduce potential toxicities associated with non-selective treatments, and preclinical studies have demonstrated significant efficacy and validated the mechanism of action for the lead candidate. GemoPharm has successfully completed pilot toxicology studies, showing no signs of toxicity. Additionally, the company is also engaged in creating humanized antibodies with high antitumor activity and low toxicity to treat conditions like multiple myeloma, utilizing cellular and biomolecular processes to enhance the immune response against infections.
Botkin.AI is a software platform specializing in medical image processing and analysis through artificial intelligence. Founded in 2015 and based in Moscow, the company focuses on enhancing the capabilities of radiologists by providing advanced tools for analyzing radiograms and assessing the risk of tumors. Utilizing deep machine learning, Botkin.AI's technology enables healthcare providers to diagnose oncological diseases, such as lung cancer, with high accuracy and at early stages. By streamlining the processing of clinical data, the platform improves diagnostic efficiency while maintaining the quality of medical conclusions, ultimately supporting better patient outcomes.
DataMatrix is software that helps its users in organizing and managing clinical research. It processes data, analyzes it, and develops documents to be accepted by the Ministry of Health of Russia, FDA, and EMA. Its products also automate the processes of clinical trial, the users manage and monitor its progress online. Data Matrix was founded in 2009 in St.Petersburg, Russia.
FK Laboratoriz
Seed Round in 2016
FK Laboratoriz has developed a drug which is a new structure of a highly specific direct thrombin inhibitor. Its expected pharmacological effects correspond to those stipulated by international standards and enable the product to compete with other medicinal products available at the EEU market. The drug was developed with the use of a combination of computer-based simulation and chemosynthesis, which are modern and recognized methods applied in the pharmaceutical industry.
Solo is a service for personalized anticancer therapy selection.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.